Information on the Target

Lyv Endo®, developed by Lyv Healthcare, is a pioneering digital medical device aimed at therapeutic treatment for endometriosis, making it the sole solution of its kind in France. The Lyv Endo® app empowers patients to implement non-pharmacological methods to enhance their quality of life and manage their condition effectively.

This funding round, led by Mutuelles Impact along with Investir&+, INCO Investissement, and Abeille Impact Investing France, followed by MGEN and various business angels, aims to position Lyv Endo® as one of the first reimbursed digital therapeutic devices by the French social security system.

Industry Overview in France

The global market for Digital Therapeutics (DTx) is projected to reach nearly €9 billion by 2028, reflecting the increasing recognition of digital health solutions in improving chronic disease management. In France, a significant public health issue persists concerning the management of endometriosis, affecting approximately 10% of women of reproductive age, translating to approximately 2.5 million women in the country.

Despite advances in endometriosis care, a recent study revealed that 83% of patients continue to experience persistent pain, often exacerbated by limited access to specialists. The annual economic burden of this condition on healthcare systems in France is estimated at €9.5 billion, highlighting the urgent need for innovative solutions.

Lyv Endo® stands out as the first certified Class I Digital Medical Device specifically designed to assist women in managing endometriosis symptoms. This application offers a multimodal support system integrating physical activity, nutrition, and mental well-being, catering to the diverse profiles of symptoms among patients.

The Rationale Behind the Deal

This fundraising initiative marks a significant step forward in Lyv's mission to transform the lives of millions of women suffering from endometriosis by becoming a leading player in the Digital Therapeutics sector across Europe. The goal is to secure reimbursement from the social security system to ensure that their solution is accessible to a broader demographic, eliminating financial discrimination in healthcare.

Lyv's innovative approach not only enhances patient care but also complements traditional medical treatments, thereby creating an invaluable tool for healthcare professionals in managing endometriosis.

Information About the Investor

Mutuelles Impact is a €95 million fund focusing on social and environmental impact in health and medico-social sectors, initiated by the Mutualité Française and managed by XAnge, alongside other partners like Investir&+. This fund is particularly interested in ventures that promote societal welfare while achieving financial sustainability.

Alongside this, INCO Ventures, which manages both INCO Investissement and Abeille Impact Investing France, focuses on inclusive and sustainable investment strategies, supporting startups that showcase potential for substantial social impact. Their involvement signifies a commitment to fostering transformative healthcare solutions.

View of Dealert

From a market perspective, investing in Lyv Healthcare and its digital solution Lyv Endo® seems to be a promising opportunity. The increasing prevalence of endometriosis and the lack of effective management solutions underline the market gap that this application addresses. Furthermore, with a solid initial funding round and the backing of influential investors, Lyv is positioned to make considerable strides in its development.

The emphasis on clinical trials to validate Lyv Endo®'s therapeutic benefits is crucial, not only for gaining social security reimbursement but also for establishing credibility within the healthcare ecosystem. Should these trials yield positive results, this could significantly enhance user engagement and market penetration.

Overall, Lyv Healthcare's mission aligns with the growing emphasis on digital health solutions in chronic disease management, demonstrating both social value and significant market potential. Investing in such innovative solutions provides an opportunity to sustain growth while contributing to vital healthcare advancements.

View Original Article